The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer.

The standard therapy for limited disease small cell lung cancer (LD-SCLC) is concurrent chemoradiotherapy and prophylactic cranial irradiation (PCI) for those who achieve complete remission (CR) or good partial response (PR) with initial therapy. On the other hand, the standard therapy for extensive disease (ED-SCLC) is chemotherapy only. After the two phase III study conducted by Slotman et al., PCI with/without thoracic radiotherapy (TRT) is also recommended in the treatment of ED-SCLC. However, a Japanese phase III study failed to confirm the benefit of PCI for patients with ED-SCLC. All studies have demonstrated the effectiveness of PCI for preventing brain metastasis, but PCI seems to have a limited influence on OS. In the 2014 edition of the Guidelines for the Treatment of Lung Cancer from the Japan Lung Cancer Society (JLCS), use of PCI for patients with ED-SCLC has been changed from "recommended" to "not recommended". Appropriate selection of patients for PCI with/without TRT is very important. It is hoped that the characteristics of patients for whom PCI with/without TRT should be considered or avoided will be better defined in the future.
AuthorsKaname Nosaki, Takashi Seto
JournalCurrent treatment options in oncology (Curr Treat Options Oncol) Vol. 16 Issue 12 Pg. 56 (Dec 2015) ISSN: 1534-6277 [Electronic] United States
PMID26467930 (Publication Type: Journal Article)
Chemical References
  • Etoposide
  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms (drug therapy, pathology, radiotherapy)
  • Chemoradiotherapy
  • Combined Modality Therapy
  • Cranial Irradiation (adverse effects)
  • Disease-Free Survival
  • Etoposide (therapeutic use)
  • Guidelines as Topic
  • Humans
  • Japan
  • Remission Induction
  • Small Cell Lung Carcinoma (drug therapy, pathology, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: